2015 ACVIM Forum Research Abstract Program

A double blind, placebo-controlled, crossover design study was preformed. Eight diabetic cats with a body condition score (BCS) ≥ 4/9 without any evidence of significant concurrent disease based on routine screening tests were recruited. All cats had been treated with glargine insulin and maintained a stable body weight for a minimum of one month prior to enrolment. Glycemic parameters monitored included serum fructosamine, fasting and postprandial blood glucose concentrations, mean blood glucose concentration for a blood glucose curve (BCG), and the total daily dose (TDD) of insulin required. Fasting and postprandial blood samples were collected for measurement of insulin and glucagon and fasting blood samples for leptin and adiponectin on the day 0, 7, 28, 42 of both arms of the study. All assays used in this study had previously been validated for use in cats.